Drug Sponsors

Biogen Idec Foundation donates $100,000 to Teach for America STEM education

Monday, August 20, 2012 09:22 AM

The Biogen Idec Foundation andTeach For America have formed a new collaboration in support of Science, Technology, Engineering and Math (STEM) education.

More... »

Cinven to acquire Mercury Pharma

Friday, August 17, 2012 02:29 PM

Cinven, a European private equity firm, reached agreement to acquire Mercury Pharma, an international specialty pharmaceutical company, from owner HgCapital.

More... »

Biogen Idec, Regulus to explore microRNA biomarkers for monitoring MS

Friday, August 17, 2012 11:38 AM

Regulus Therapeutics, a San Diego-based biopharmaceutical company focused on medicines targeting microRNAs, has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS).

More... »

Ark Therapeutics signs a letter of intent with EMD Millipore

Friday, August 17, 2012 11:13 AM

Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. 

More... »

TG Therapeutics, Rhizen ink global agreement for TGR-1202

Friday, August 17, 2012 11:08 AM

TG Therapeutics, a clinical-stage biopharmaceutical company of New York, N.Y., and Rhizen Pharmaceuticals, a Switzerland-based biopharmaceutical company, have entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen's lead product candidate, TGR-1202, a novel PI3K delta inhibitor previously referred to as RP5264.

More... »

Zenobia partners with Alzheimer's Drug Discovery Foundation

Wednesday, August 15, 2012 11:54 AM

Zenobia Therapeutics, a fragment-based discovery company focused on central nervous system (CNS) disease based in San Diego, has formed a strategic partnership to provide Alzheimer's Drug Discovery Foundation (ADDF) researchers access to Zenobia's discovery platform.

More... »

Arrowhead enters into antibody candidate evaluation agreement with Merck

Wednesday, August 15, 2012 11:27 AM

Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has entered into an agreement with global healthcare company Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.

More... »

AZ, Pfizer enter agreement for OTC Nexium

Wednesday, August 15, 2012 09:41 AM

AstraZeneca, a global biopharmaceutical company, has entered into an agreement with Pfizer, a global research-based pharmaceutical company, for the over-the-counter (OTC) rights for Nexium (esomeprazole magnesium), a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD).

More... »

Elcelyx extends Series B financing for weight loss and diabetes

Monday, August 13, 2012 02:51 PM

Elcelyx Therapeutics, a San Diego-based biotechnology company, has secured $4 million of a $7 million extension of its Series B private equity financing. Existing investors Morgenthaler Ventures, Kleiner Perkins Caufield & Byers and Technology Partners all participated in the extension.

More... »

Quintiles acquires Expression Analysis to advance personalized medicine

Monday, August 13, 2012 12:02 PM

Quintiles, a fully integrated biopharmaceutical services company, has acquired Expression Analysis (EA), a Durham, N.C.-based provider of genomics testing and analysis to biopharma, academic, government and non-profit customers. Terms of the transaction were not disclosed.

More... »